Nervous System News and Research

Latest Nervous System News and Research

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Orasi Medical today announced that it has entered an agreement with H. Lundbeck A/S to study the effect of Lundbeck central nervous system compounds on the human brain.

15 Jun 2010

Study: Mentally active lifestyle may protect against memory and learning problems in MS

A new study shows that a mentally active lifestyle may protect against the memory and learning problems that often occur in multiple sclerosis. The study is published in the June 15, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

15 Jun 2010

Clinical Data closes public offering of newly issued shares of common stock

Clinical Data, Inc. today announced the closing of its previously announced public offering of 2,237,412 newly issued shares of common stock, including 291,836 shares sold pursuant to the full exercise of an over-allotment option granted to the underwriters, at a price to the public of $14.30 per share.

15 Jun 2010

Georgia Bioscience Commercialization Center launched

Lt. Governor Casey Cagle today joined Georgia Bio, the Georgia Research Alliance, the Metro Atlanta Chamber and the Innovation Crescent business community in announcing the launch of the Georgia Bioscience Commercialization Center (GBCC), which will act as a start-up catalyst and resource center for bioscience entrepreneurs in Georgia.

15 Jun 2010

Pediatric oncologist describes current state of science in combating neuroblastoma

Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge—much of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia.

15 Jun 2010

Researchers establish link between air pollution and SDB

Researchers from Brigham and Women's Hospital and the Harvard School of Public Health have established the first link between air pollution and sleep-disordered breathing, a known cause of cardiovascular diseases.

15 Jun 2010

UCB announces availability of Vimpat oral solution formulation

UCB today announced the availability of an oral solution formulation of Vimpat- (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older. Vimpat 10 mg/mL solution is now available in U.S. pharmacies.

14 Jun 2010

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

MultiCell Technologies, Inc. has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned Phase IIb clinical trial in the United Kingdom for MCT-125, the Company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF).

14 Jun 2010

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

Upsher-Smith Laboratories, Inc. today announced the initiation of a global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology. USL255 is designed to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.

14 Jun 2010

New bacterial strain could help in long-term cleanup of oil spills

Researchers have discovered a new strain of bacteria that can produce non-toxic, comparatively inexpensive "rhamnolipids," and effectively help degrade polycyclic aromatic hydrocarbons, or PAHs - environmental pollutants that are one of the most harmful aspects of oil spills.

14 Jun 2010

National MS Society commits over $2.4M to support 7 CCSVI research projects

Over $2.4 million has been committed by the National MS Society (USA) and the MS Society of Canada to support 7 new research projects focusing on the role of CCSVI in MS.

14 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

Researchers identify 2,630 proteins that reside in human spinal fluid

A research team has sharply expanded scientific knowledge of the composition of human spinal fluid. The researchers have identified 2,630 proteins that reside in fluid that is considered "normal," a number nearly three times as great as the total number of proteins previously identified. Another striking finding was that more than half (56%) of the proteins were relatively unique to the spinal fluid and not found in blood.

14 Jun 2010

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

A virus infection can incite the body to attack its own nerve tissue by activating unusual, disease-fighting cells with receptors for both viral and nerve proteins. The dual-receptor observation suggests a way brain and spinal cord nerve damage might be triggered in susceptible young adults afflicted with multiple sclerosis.

11 Jun 2010

Waismann Method survey: 88% of individuals taken prescription painkillers for chronic pain relief

According to a recent survey conducted by the Waismann Method of opiate detoxification, doctors prescribing medication for the treatment of chronic pain were found to be the leading source of prescription painkiller use. Approximately 88 percent of all respondents stated they began taking prescription painkillers for chronic pain relief, with an astounding 70 percent of these individuals believing that they experience the same or a greater amount of pain than when originally prescribed painkillers.

11 Jun 2010

BMS employees across Canada taking part in third annual Community Action Day

More than 300 employees of Bristol-Myers Squibb Canada will get the day off from their regular work today, but they won't be taking it easy. Instead, they will be joining company retirees and members of their own families in helping out at a variety of community and charitable organizations as part of the company's third annual BMS Community Action Day.

11 Jun 2010

Universal Bioenergy, NDR Energy Group sponsor charitable event to raise funds for National Multiple Sclerosis Society

Universal Bioenergy Inc., an alternative energy company, and NDR Energy Group, announced today that they are sponsoring a major charitable event to help raise funds for the National Multiple Sclerosis Society.

11 Jun 2010

Interpretation of multiple gene function may hold clue to autism

Deciphering the functions of multiple rare genes may be at the core of understanding the genetic factors that cause autism spectrum disorders (ASDs), according to a new study published June 9 in the journal Nature by dozens of top autism researchers around the world, including Yale Child Study Center Director Fred R. Volkmar, M.D.

11 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

Nervous System News and Research

Latest Nervous System News and Research

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Study: Mentally active lifestyle may protect against memory and learning problems in MS

Clinical Data closes public offering of newly issued shares of common stock

Georgia Bioscience Commercialization Center launched

Pediatric oncologist describes current state of science in combating neuroblastoma

Researchers establish link between air pollution and SDB

UCB announces availability of Vimpat oral solution formulation

MultiCell retains CDSS to manage MCT-125 Phase IIb clinical trial for PMSF in UK

Upsher-Smith commences global USL255 Phase III clinical trial for management of epilepsy

New bacterial strain could help in long-term cleanup of oil spills

National MS Society commits over $2.4M to support 7 CCSVI research projects

Olfactory function tests could help in treating patient in early stages of PD

Researchers identify 2,630 proteins that reside in human spinal fluid

White blood cells with receptors for both virus and nerve proteins may assault nerves after fighting infection

Waismann Method survey: 88% of individuals taken prescription painkillers for chronic pain relief

BMS employees across Canada taking part in third annual Community Action Day

Universal Bioenergy, NDR Energy Group sponsor charitable event to raise funds for National Multiple Sclerosis Society

Interpretation of multiple gene function may hold clue to autism

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Nervous System News and Research

Latest Nervous System News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in